HRP20191945T1 - Poboljšana il-6-protutijela - Google Patents
Poboljšana il-6-protutijela Download PDFInfo
- Publication number
- HRP20191945T1 HRP20191945T1 HRP20191945TT HRP20191945T HRP20191945T1 HR P20191945 T1 HRP20191945 T1 HR P20191945T1 HR P20191945T T HRP20191945T T HR P20191945TT HR P20191945 T HRP20191945 T HR P20191945T HR P20191945 T1 HRP20191945 T1 HR P20191945T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- mutation
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims 26
- 102000036639 antigens Human genes 0.000 claims 26
- 108091007433 antigens Proteins 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 26
- 230000035772 mutation Effects 0.000 claims 11
- 102000001708 Protein Isoforms Human genes 0.000 claims 6
- 108010029485 Protein Isoforms Proteins 0.000 claims 6
- 230000009885 systemic effect Effects 0.000 claims 6
- 238000009825 accumulation Methods 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 229960002833 aflibercept Drugs 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 2
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000028006 Corneal injury Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (21)
1. Protutijelo ili fragment koji veže antigen, naznačeno time, da obuhvaća varijabilno područje teškog lanca koje sadrži SEQ ID NO:37 i varijabilno područje lakog lanca koje sadrži SEQ ID NO:38.
2. Protutijelo ili fragment koji veže antigen, naznačeno time, da obuhvaća sekvencu teškog lanca koja sadrži SEQ ID NO:41 i sekvencu lakog lanca koja sadrži SEQ ID NO:42; ili time, da protutijelo ili fragment koji veže antigen i koji obuhvaća sekvencu teškog lanca koja sadrži SEQ ID NO:41 i sekvencu lakog lanca koja sadrži SEQ ID NO:42, obuhvaća mutaciju (npr. 1, 2, 3 ili 4 mutacije) na jednoj ili više pozicija koje odgovaraju sljedećima: H311, D313, I254 ili H436 (numeriranje je kao u SEQ ID NO:41).
3. Fab, naznačen time, da obuhvaća sekvencu teškog lanca koja sadrži SEQ ID NO:39 ili SEQ ID NO:54 i sekvencu lakog lanca koja sadrži SEQ ID NO:42.
4. Protutijelo ili fragment koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da protutijelo ili fragment koji veže antigen ima poboljšano zadržavanje u oku kada se primjenjuje intravitrealno, u usporedbi s tocilizumabom i/ili afliberceptom.
5. Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 i 4, naznačeno time, da protutijelo ili fragment koji veže antigen obuhvaća mutaciju (npr. 1, 2, 3 ili 4 mutacije) na jednoj ili više pozicija koje odgovaraju sljedećima: H311, D313, I254 ili H436 (numeriranje je kao u SEQ ID NO:41).
6. Protutijelo ili fragment koji veže antigen prema patentnom zahtjevu 2 ili 5, naznačeno time, da je navedena mutacija odabrana od jedne ili više od sljedećih: H311A, H311E, H311N, D313T, I254A, I254R i H436A.
7. Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 2 i 5 do 6, naznačeno time, da navedena mutacija je H311A mutacija (numeriranje je kao u SEQ ID NO:41).
8. Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 2 i 5 do 7, naznačeno time, da navedena mutacija smanjuje sistemsku akumulaciju protutijela ili fragmenta koji veže antigen, u usporedbi sa sistemskom akumulacijom protutijela ili fragmenta koji veže antigen, koji ne sadrži mutaciju.
9. Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 2 i 5 do 7, naznačeno time, da navedena mutacija smanjuje sistemsku akumulaciju protutijela ili fragmenta koji veže antigen, u usporedbi sa sistemskom akumulacijom protutijela ili fragmenta koji veže antigen, koji ne sadrži mutaciju, gdje se sistemska akumulacija procjenjuje nakon intravitrealne primjene protutijela ili fragmenta koji veže antigen.
10. Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time, da protutijelo ili fragment koji veže antigen ima sistemski poluživot koji je kraći nego što je to kod tocilizumaba i/ili aflibercepta.
11. Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 10, naznačeno time, da protutijelo ili fragment koji veže antigen je izoform IgG2-A ili izoform IgG2-A/B, ali nije izoform IgG2-B.
12. Protutijelo ili fragment koji veže antigen, naznačeno time, da obuhvaća sekvencu teškog lanca koja sadrži SEQ ID NO:47 i sekvencu lakog lanca koja sadrži SEQ ID NO:42.
13. Pripravak, naznačen time, da obuhvaća protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 12 i prema potrebi, farmaceutski prihvatljiv nosač.
14. Pripravak prema patentnom zahtjevu 13, naznačen time, da pripravak obuhvaća najmanje 60, 70, 80, 90, 95 ili 99% od izoforma IgG2-A protutijela ili izoforma IgG2-A/B protutijela, ili od njihove kombinacije.
15. Pripravak prema patentnom zahtjevu 13 ili 14, naznačen time, da pripravak obuhvaća manje od 10%, 5%, 2%, 1% ili 0,5% od izoforma IgG2-B protutijela.
16. Pripravak prema bilo kojem od patentnih zahtjeva 13 do 15, ili protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 12, naznačeni time, da se upotrebljavaju u liječenju bolesti povezane s IL-6.
17. Pripravak za uporabu prema patentnom zahtjevu 16, ili protutijelo ili fragment koji veže antigen za uporabu prema patentnom zahtjevu 16, naznačeni time, da se upotrebljavaju u liječenju očne bolesti koja je karakteristična po povišenoj razini IL-6.
18. Pripravak prema bilo kojem od patentnih zahtjeva 13 do 15, ili protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 12, naznačeni time, da se upotrebljavaju u liječenju dijabetičkog makularnog edema (DME), dijabetičke retinopatije, suhih očiju (npr. bolest suhog oka ili sindrom suhog oka), alergijskog konjunktivitisa, uveitisa, makularne degeneracije vezane uz dob (AMD), proliferativne dijabetičke retinopatije (PDR), regmatogene retinalne ablacije (RRA), okluzije retinalne vene (ORV), optičkog neuromijelitisa (ONM), transplantacije rožnice, abrazije rožnice, ili fizičke ozljede oka.
19. Nukleinska kiselina, naznačena time, da ona obuhvaća sekvencu koja kodira protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 12.
20. Vektor, naznačen time, da on obuhvaća nukleinsku kiselinu prema patentnom zahtjevu 19.
21. Stanica, naznačena time, da ona obuhvaća vektor prema patentnom zahtjevu 20.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462077105P | 2014-11-07 | 2014-11-07 | |
US201462087448P | 2014-12-04 | 2014-12-04 | |
US201562247705P | 2015-10-28 | 2015-10-28 | |
PCT/US2015/059532 WO2016073890A1 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
EP15797538.4A EP3215530B9 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191945T1 true HRP20191945T1 (hr) | 2020-01-24 |
Family
ID=54602042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191945TT HRP20191945T1 (hr) | 2014-11-07 | 2019-10-25 | Poboljšana il-6-protutijela |
Country Status (33)
Country | Link |
---|---|
US (2) | US11142571B2 (hr) |
EP (3) | EP3632931A1 (hr) |
JP (1) | JP6594438B2 (hr) |
KR (2) | KR102636726B1 (hr) |
CN (1) | CN107249631B (hr) |
AU (1) | AU2015342882B2 (hr) |
BR (1) | BR112017008672A2 (hr) |
CA (1) | CA2965689C (hr) |
CL (1) | CL2017001135A1 (hr) |
CO (1) | CO2017005404A2 (hr) |
CR (1) | CR20170231A (hr) |
DK (1) | DK3215530T3 (hr) |
EA (1) | EA035199B1 (hr) |
ES (1) | ES2756275T3 (hr) |
HK (1) | HK1244008A1 (hr) |
HR (1) | HRP20191945T1 (hr) |
HU (1) | HUE046181T2 (hr) |
IL (1) | IL251858B (hr) |
MA (1) | MA51554A (hr) |
MX (2) | MX2017005992A (hr) |
MY (1) | MY185114A (hr) |
NZ (1) | NZ731090A (hr) |
PE (1) | PE20171107A1 (hr) |
PH (1) | PH12017500809A1 (hr) |
PL (1) | PL3215530T3 (hr) |
PT (1) | PT3215530T (hr) |
RS (1) | RS59805B1 (hr) |
SA (1) | SA517381458B1 (hr) |
SG (2) | SG10202103420PA (hr) |
SI (1) | SI3215530T1 (hr) |
UA (1) | UA122673C2 (hr) |
WO (1) | WO2016073890A1 (hr) |
ZA (1) | ZA201702985B (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA42924A (fr) | 2015-09-23 | 2018-08-01 | Hoffmann La Roche | Variants optimisés d'anticorps anti-vegf |
JP2019510078A (ja) * | 2016-02-23 | 2019-04-11 | セセン バイオ, インコーポレイテッド | Il−6アンタゴニスト製剤およびその使用 |
MX2019007144A (es) * | 2016-12-19 | 2019-10-07 | Glenmark Pharmaceuticals Sa | Nuevos agonistas de tnfr y sus usos. |
SG11201908650PA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Optimized antibody compositions for treatment of ocular disorders |
SG10202107829YA (en) | 2017-03-22 | 2021-08-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
JP2023517345A (ja) | 2020-03-13 | 2023-04-25 | ジェネンテック, インコーポレイテッド | 抗インターロイキン-33抗体及びその使用 |
WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
AU2021361108A1 (en) | 2020-10-15 | 2023-05-25 | F. Hoffmann-La Roche Ag | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery |
CN114525235B (zh) * | 2022-02-25 | 2023-07-14 | 郑州大学 | 一种提高人表皮生长因子分泌生产效率的方法 |
WO2024088921A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Predicting response to il-6 antagonists |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
TW311927B (hr) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
WO2000034784A1 (en) | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
KR100913714B1 (ko) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
AU2003234439A1 (en) | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
WO2004045507A2 (en) * | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
US7968690B2 (en) | 2003-12-23 | 2011-06-28 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
EP1776384B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant fc regions |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1966244B1 (en) | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
JP2009529339A (ja) | 2006-03-13 | 2009-08-20 | アブリンクス エン.ヴェー. | Il−6を標的とするアミノ酸配列およびそれを含みil−6介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
EP2021463B1 (en) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
SI2164514T1 (sl) | 2007-05-21 | 2017-04-26 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
EP3124044A1 (en) | 2007-09-14 | 2017-02-01 | Sanofi Pasteur Biologics, LLC | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
WO2009070243A2 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
EP2249809A1 (en) | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
EP2837388A1 (en) | 2008-08-05 | 2015-02-18 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
ES2395231T3 (es) | 2008-09-12 | 2013-02-11 | Kdf Co., Ltd. | Dispositivo de proyección de agua en forma de surtidor |
WO2010039750A2 (en) | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
BRPI0921319A2 (pt) | 2008-11-26 | 2018-10-16 | Glaxo Group Ltd | composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica |
SG2014007637A (en) | 2009-01-29 | 2014-03-28 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
AU2011277999A1 (en) | 2010-07-12 | 2013-01-10 | Covx Technologies Ireland Limited | Multifunctional Antibody Conjugates |
CN104428315B (zh) | 2012-07-13 | 2017-09-29 | 罗氏格黎卡特股份公司 | 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用 |
BR112015008186A2 (pt) | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
SG11201502876RA (en) * | 2012-11-08 | 2015-06-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
JP2016531901A (ja) | 2013-07-12 | 2016-10-13 | オプソテック コーポレイションOphthotech Corporation | 眼科症状を処置するまたは予防するための方法 |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 BR BR112017008672-7A patent/BR112017008672A2/pt active Search and Examination
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 NZ NZ731090A patent/NZ731090A/en unknown
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active IP Right Grant
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 MX MX2017005992A patent/MX2017005992A/es unknown
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 KR KR1020247004699A patent/KR20240023450A/ko not_active Application Discontinuation
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 EP EP23189385.0A patent/EP4268843A3/en active Pending
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en active Application Filing
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-02 PH PH12017500809A patent/PH12017500809A1/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2018
- 2018-03-10 HK HK18103370.4A patent/HK1244008A1/zh unknown
-
2019
- 2019-10-25 HR HRP20191945TT patent/HRP20191945T1/hr unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191945T1 (hr) | Poboljšana il-6-protutijela | |
HRP20210517T1 (hr) | Pripravci i postupci za protutijela usmjerena na epo | |
Rosenfeld et al. | Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration | |
JP2015231997A5 (hr) | ||
JP2016504416A5 (hr) | ||
JP2019510078A5 (hr) | ||
US20230025418A1 (en) | Vegfr-fc fusion protein formulations | |
HRP20210736T1 (hr) | Protutijela anti-htra1 i načini njihove uporabe | |
JP2016065094A5 (hr) | ||
JP2017535285A5 (hr) | ||
ES2706059T3 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y derivado de L-arginina y una inyección que incluye la composición | |
WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
Cohn et al. | Meningococcal vaccines: current issues and future strategies | |
JP2017510567A5 (hr) | ||
US20210353713A1 (en) | Formulations comprising a tris buffer and a protein | |
PH12020551641A1 (en) | Compositions and methods for treating macular dystrophy | |
RU2018145017A (ru) | Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком | |
JP2018527327A5 (hr) | ||
HRP20211838T1 (hr) | Krnji protein vp4 rotavirusa i njegova primjena | |
JP2016508372A5 (hr) | ||
Chu et al. | Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells | |
BR112016023980A2 (pt) | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) | |
MX2022000780A (es) | Fragmento fab del anticuerpo anti-vegf humanizado y uso del mismo. | |
Parodi et al. | Antivascular endothelial growth factors for inflammatory chorioretinal disorders | |
Zlontnik et al. | Experimental infection of monkeys with viruses of the tick-borne encephalitis complex: degenerative cerebellar lesions following inapparent forms of the disease or recovery from clinical encephalitis. |